isoproterenol has been researched along with Pulmonary Arterial Hypertension in 1 studies
Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.
isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.
Pulmonary Arterial Hypertension: A progressive rare pulmonary disease characterized by high blood pressure in the PULMONARY ARTERY.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stephens, OR | 1 |
| Weiss, K | 1 |
| Frimel, M | 1 |
| Rose, JA | 1 |
| Sun, Y | 1 |
| Asosingh, K | 1 |
| Farha, S | 1 |
| Highland, KB | 1 |
| Prasad, SVN | 1 |
| Erzurum, SC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pulmonary Arterial Hypertension Treatment With Carvedilol for Heart Failure[NCT01586156] | 30 participants (Actual) | Interventional | 2012-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
We hypothesized that carvedilol would not worsen 6 minute walk distance. (NCT01586156)
Timeframe: 6 months
| Intervention | meters (Mean) | ||
|---|---|---|---|
| baseline | 3 months | 6 months | |
| Escalation-dose Carvedilol | 438 | 438 | 450 |
| Low-fixed-dose Carvedilol | 504 | 504 | 486 |
| Placebo Arm | 404 | 412 | 453 |
We hypothesize that use of carvedilol in patients with PAH will increase beta- adrenergic receptor availability, and this will be measurable as a increase in alprenolol binding over time of drug use. (NCT01586156)
Timeframe: 6 months
| Intervention | abritrary units (Mean) | |
|---|---|---|
| baseline | 6 months | |
| Escalation-dose Carvedilol | 82779 | 83730 |
| Low-fixed-dose Carvedilol | 85230 | 84554 |
| Placebo Arm | 92254 | 79083 |
We hypothesize that use of carvedilol in patients with PAH (Pulmonary Arterial Hypertension) will decrease the cardiac glucose utilization, and this will be measurable as a drop in fasting FDG-PET standardized uptake values of the heart at 6 months as compared to baseline (NCT01586156)
Timeframe: 6 months
| Intervention | standardized uptake value (SUV) (Median) | |
|---|---|---|
| baseline FDG-PET | 6 month FDG-PET | |
| Escalation-dose Carvedilol | 0.9 | 0.7 |
| Low-fixed-dose Carvedilol | 0.6 | 0.6 |
| Placebo Arm | 1.0 | 0.8 |
We hypothesized that carvedilol would be safe and tolerable and thus that Left ventricular cardiac output, a measure of heart function, would not decrease in participants on carvedilol. (NCT01586156)
Timeframe: 6 months
| Intervention | L/min (Mean) | ||
|---|---|---|---|
| baseline | 3 months | 6 months | |
| Escalation-dose Carvedilol | 4.5 | 4.8 | 4.9 |
| Low-fixed-dose Carvedilol | 5.2 | 4.6 | 4.7 |
| Placebo Arm | 4.7 | 4.7 | 4.5 |
We hypothesized that RVSP might decrease in participants on carvedilol. (NCT01586156)
Timeframe: 6 months
| Intervention | mm Hg (Mean) | ||
|---|---|---|---|
| baseline | 3 months | 6 months | |
| Escalation-dose Carvedilol | 63 | 54 | 64 |
| Low-fixed-dose Carvedilol | 63 | 59 | 51 |
| Placebo Arm | 76 | 78 | 66 |
We hypothesized that carvedilol would be safe and tolerable and thus that NT-BNP, a measure of heart failure, would not increase in participants on carvedilol. (NCT01586156)
Timeframe: 6 months
| Intervention | pg/ml (Median) | |||
|---|---|---|---|---|
| baseline | 1 month | 3 months | 6 months | |
| Escalation-dose Carvedilol | 127 | 120 | 169 | 146 |
| Low-fixed-dose Carvedilol | 57 | 92 | 79 | 52 |
| Placebo Arm | 170 | 183 | 152 | 293 |
We hypothesize that use of carvedilol in patients with PAH will increase beta adrenergic receptor function and this will be measurable as an increase in cAMP measured in the urine at 6 months in participants in dose escalation carvedilol. (NCT01586156)
Timeframe: 6 months
| Intervention | umol/g (Median) | |||
|---|---|---|---|---|
| baseline | 1 month | 3 months | 6 months | |
| Escalation-dose Carvedilol | 1.0 | 0.7 | 1.5 | 1.0 |
| Low-fixed-dose Carvedilol | 0.6 | 0.8 | 0.6 | 0.7 |
| Placebo Arm | 1.4 | 1.3 | 1.2 | 1.4 |
1 other study available for isoproterenol and Pulmonary Arterial Hypertension
| Article | Year |
|---|---|
Interdependence of hypoxia and β-adrenergic receptor signaling in pulmonary arterial hypertension.
Topics: Adrenergic beta-Antagonists; Animals; Familial Primary Pulmonary Hypertension; Heart Ventricles; Hum | 2019 |